Table 3.
Participants’ responses to the open-ended question: What questions or issues related to medications for osteoporosis would you like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines in order to help doctors and other healthcare professionals in making treatment decisions with their patients?
| Number of participants who provided answers | N = 113 |
|---|---|
| Total references* 135 |
|
| Pharmacologic treatment | 75 |
| Benefits and harms | 55 |
| Cost of medications | 7 |
| Drug-drug interactions | 5 |
| New medications | 4 |
| Drug holiday | 2 |
| Access to medications | 1 |
| Time to start with a therapy | 1 |
| Nutrition and supplements | 19 |
| Supplements recommendations | 12 |
| Dietary recommendations | 7 |
| Alternative therapies | 14 |
| Education | 11 |
| For patients/families/caregivers—source of information they can trust | 6 |
| For healthcare professionals | 5 |
| Monitoring-prevention | 8 |
| Response to treatment/BMD | 6 |
| Prevention | 1 |
| Access to specialists | 1 |
| Pain management | 6 |
| Other | 2 |
*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question